BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [PMID: 36157155 DOI: 10.5306/wjco.v13.i7.641]
URL: https://www.wjgnet.com/2218-4333/full/v13/i7/641.htm
Number Citing Articles
1
Yusuke Nakazawa, Kanako Watanabe, Ako Gannichida, Tadashi Uwagawa, Takashi Kawakubo. Significance of Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Anamorelin for Cancer CachexiaCureus 2025;  doi: 10.7759/cureus.77795
2
Yusuke Nakazawa, Ako Gannichida, Hirofumi Utsumi, Jun Araya, Takashi Kawakubo. Early Prediction of Pembrolizumab-Induced Hypothyroidism Based on the Neutrophil-to-Lymphocyte RatioCureus 2025;  doi: 10.7759/cureus.80049
3
Xinyu Zhang, Bei Zhang, Danfei Li, Yunchao Yang, Sen Lin, Ruiqi Zhao, Yijia Li, Lisheng Peng. Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysisFrontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1528084
4
Hong-Rui Lu, Peng-Fei Zhu, Ya-Ya Deng, Zhe-Ling Chen, Liu Yang. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysisClinical and Translational Oncology 2023; 26(5): 1106 doi: 10.1007/s12094-023-03313-3
5
Wei Zhang, Yifei Tan, Yuquan Li, Jiang Liu. Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysisFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1234142